Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Here’s Why

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) shares dropped 0.5% during mid-day trading on Monday . The company traded as low as $1.88 and last traded at $1.95. Approximately 9,989 shares traded hands during mid-day trading, a decline of 44% from the average daily volume of 17,924 shares. The stock had previously closed at $1.96.

Alaunos Therapeutics Stock Down 0.5 %

The stock has a fifty day moving average of $2.20 and a 200-day moving average of $3.64.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.